Welcome to our dedicated page for Hcw Biologics news (Ticker: HCWB), a resource for investors and traders seeking the latest updates and insights on Hcw Biologics stock.
HCW Biologics Inc. develops fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune disorders, proinflammatory diseases, cancer and senescence-associated dysplasia. Its recurring company updates center on the TOBI and TRBC discovery platforms and product candidates such as HCW9302, an IL-2 fusion immunotherapeutic, HCW11-018b, a T-cell engager for solid tumors, and HCW9206, a multi-cytokine fusion protein reagent used in CAR-T manufacturing research.
News about HCWB also covers clinical and preclinical program disclosures, research publications, licensing activity involving HCW11-006 and Trimmune, operating and financial results, capital-structure matters, shareholder voting topics and Nasdaq listing-status developments.
HCW Biologics (NASDAQ: HCWB) announced its Chief Scientific Officer, Peter Rhode, PhD, participated in a Virtual Investor “What This Means” segment highlighting the company’s lead candidate HCW11-040, a pembrolizumab-based, tetra-specific fusion protein built on the TRBC platform.
HCW11-040 combines pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components (TGF-β traps). Preclinical testing reportedly shows expansion of exhausted T cells (TPEX) without causing side effects. Detailed preclinical data will be presented in a poster at SITC on November 8, 2025.
HCW Biologics (NASDAQ: HCWB) announced it will participate in the 2025 Maxim Growth Summit held October 22–23 at The Hard Rock Hotel NYC.
Founder and CEO Dr. Hing C. Wong will meet one-on-one with institutional investors and senior Maxim analysts; the program includes CEO roundtables and keynote speakers. The company described the event as an opportunity to discuss its clinical-stage immunotherapy programs linking chronic inflammation and disease.
HCW Biologics (NASDAQ: HCWB) will present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, MD (November 5–9, 2025).
Presentations on November 7–8 highlight IND‑enabling results for three lead drug candidates built on HCW’s proprietary TRBC platform: a Class III multi-specific T‑cell engager (Abstract 915), a Class II tetra‑specific pembrolizumab‑based immunotherapeutic (Abstract 1014), and a Class I cytokine fusion molecule HCW11‑006 (Abstract 276). Posters are scheduled in the Prince George ABC Exhibit Halls at Gaylord National Resort and Convention Center on November 7 and 8, 2025.
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, presented its second-generation T-Cell Engager (TCE) program in a Virtual Investor segment. Chief Scientific Officer Dr. Peter Rhode discussed the company's recent advancements in their TCE technology.
The company's improved TCE program demonstrates enhanced manufacturability, safety profile, and effectiveness against solid tumors. These second-generation TCEs aim to address key limitations of first-generation treatments, including complex manufacturing, tolerability issues, and limited efficacy for solid tumors. HCW Biologics has positioned itself among select biotech companies developing innovative TCEs that can overcome resistance mechanisms.
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced that Wugen, a company in which it holds a minority stake, has secured a $115 million equity financing led by Fidelity Management & Research Company. The financing included participation from several prominent life sciences investors.
HCW Biologics' stake in Wugen originated from a 2020 Exclusive License Agreement, which has generated $16.2 million in revenues for HCW through license fees (paid in cash and Wugen stock) and clinical material sales. The funding will support Wugen's development of allogeneic, off-the-shelf CAR-T cell therapies.
HCW Biologics (NASDAQ: HCWB) has selected HCW11-040, one of its proprietary pembrolizumab-based immune checkpoint inhibitors, as its lead product candidate for solid tumor treatment. The molecule combines pembrolizumab (Keytruda®) with IL-7, IL-15, and TGF-β receptor components.
In preclinical studies, HCW11-040 demonstrated superior performance compared to pembrolizumab monotherapy in several key areas: immune-cell activation, tumor infiltration, and cancer cell cytotoxicity. Notably, the compound showed the ability to expand TPEX cells without triggering cytokine storm when administered subcutaneously at projected efficacious doses.
The company will now advance HCW11-040 to late-phase IND-enabling studies, including manufacturing cell bank creation, chemistry manufacture control process development, and preclinical GLP toxicology studies.
HCW Biologics (NASDAQ: HCWB) has announced positive results from its non-human primate study for second-generation T-cell engagers (TCEs) targeting solid tumors. The company's lead drug candidate demonstrated strong safety profile and tolerance at doses significantly higher than efficacious levels.
The company's proprietary TRBC platform technology has developed TCEs targeting tissue factor and mesothelin, showing potent anti-pancreatic cancer activities in preclinical studies. Key advantages include reduced immunosuppression in tumor microenvironment, cost-effective manufacturing, and potential treatment for multiple solid tumors including pancreatic cancer and glioblastoma.
Notably, preclinical studies showed 100% survival rate in tumor-bearing mice treated with their TCE candidate. The company is now positioned to seek high-value corporate partnerships to advance development.
HCW Biologics (NASDAQ: HCWB) has developed a breakthrough second-generation pembrolizumab-based immune checkpoint inhibitor (ICI) using its proprietary TRBC platform technology. The company's novel immunotherapeutic has shown superior performance against solid tumors, particularly pancreatic and ovarian cancer, in preclinical studies.
The new therapy addresses key limitations of current ICIs, which have less than 20% response rates despite generating $40 billion in worldwide sales in 2024. HCWB's enhanced version not only blocks checkpoint receptors but also neutralizes TGF-β and promotes immune cell infiltration into tumors, demonstrating better efficacy than standard pembrolizumab in preclinical trials.
Dr. Hing C. Wong, CEO, will present detailed IND-enabling study results at Nova Southeastern University on September 12, 2025.
HCW Biologics (NASDAQ: HCWB) reported Q2 2025 financial results and business updates. The company completed a $5.0 million equity offering with an institutional investor and extinguished $7.7 million in debt. Key developments include WY Biotech's acceptance of their technical report with a $7.0 million license fee due by September 30, 2025, and a one-year suspension of the Wugen License Agreement to seek alternative licensing for HCW9206.
Financial results showed Q2 2025 revenues of $6,550, down from $618,854 in Q2 2024. R&D expenses decreased 40% to $1.2 million, while G&A expenses increased 31% to $2.1 million. Net loss improved to $1.9 million from $15.3 million in Q2 2024. The company regained compliance with Nasdaq listing requirements but noted substantial going concern doubts without additional funding.
[ "Successful completion of $5.0 million equity offering", "Extinguishment of $7.7 million in debt through restructuring or conversion", "Regained compliance with all Nasdaq listing requirements", "40% reduction in R&D expenses to $1.2 million", "Net loss improved significantly to $1.9 million from $15.3 million YoY", "Potential $7.0 million license fee from WY Biotech due by September 2025" ]HCW Biologics (NASDAQ: HCWB) announced successful development of second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using their proprietary TRBC platform technology. The company's lead T-cell engagers target tissue factor and mesothelin, demonstrating potent anti-pancreatic cancer activities in preclinical studies.
The breakthrough technology not only targets cancer antigens and activates T cells but also reduces immunosuppression in the tumor microenvironment. In preclinical studies, 100% survival was observed in tumor-bearing mice treated with TRBC-based T-cell engagers, while untreated mice did not survive. Dr. Hing C. Wong, Founder and CEO, will present these IND-enabling study results at the Phoenix Best Science Series on June 27, 2025.